Citations

Clear

2117 citation(s) found for "Mayo, Steven".

UROLOGIC DISEASES IN AMERICA PROJECT: BENIGN PROSTATIC HYPERPLASIA
Wei, John T., Calhoun, Elizabeth A. , Jacobsen, Steven J.

Mayo Clinic

Journal of Urology | March 2, 2005 | Volume: 173 | Issue: 4 | Pages: 1256-1261

10.1097/01.ju.0000155709.37840.fe | PMID 15758764 Get It

IS BENIGN PROSTATIC HYPERPLASIA A RISK FACTOR FOR CHRONIC RENAL FAILURE?
Lieber, Michael M., Jacobsen, Steven J. , Rule, Andrew D.

Mayo Clinic

Journal of Urology | February 11, 2005 | Volume: 173 | Issue: 3 | Pages: 691-696

10.1097/01.ju.0000153518.11501.d2 | PMID 15711245 Get It

In Reply
Sargent, Daniel J. , Loprinzi, Charles L. , Alberts, Steven R. , Gill, Sharlene , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | January 19, 2005 | Volume: 23 | Issue: 3 | Pages: 654-655

10.1200/jco.2005.05.260 Get It

Heart Failure and Death After Myocardial Infarction in the Community
Bursi, Francesca , Enriquez-Sarano, Maurice, Jacobsen, Steven J. , Weston, Susan A., Meverden, Ryan A., Roger, Véronique L. , Enriquez‐Sarano, Maurice , Nkomo, Vuyisile T. , Enriquez-Sarano, Maurice , Bursi, Francesca

Mayo Clinic

Circulation | January 17, 2005 | Volume: 111 | Issue: 3 | Pages: 295-301

10.1161/01.cir.0000151097.30779.04 | PMID 15655133 Get It

Background— In case series, mitral regurgitation (MR) increased the risk of death after myocardial infarction (MI), yet the prevalence of MR, its incremental prognostic value over ejection fraction (EF), and its association with heart failure and death after MI in the community is not known. Methods and Results— The prevalence of MR and its association with heart failure and death were examined among 1331 patients within a geographically defined MI incidence cohort between 1988 and 1998. Echocardiography was performed within 30 days after MI in 773 patients (58%), and MR was present in 50% of cases, mild in 38%, and moderate or severe in 12%. Among patients with MR, a murmur was inconsistently detected clinically. After 4.7±3.3 years of follow-up, 109 episodes of heart failure and 335 deaths occurred. There was a graded positive association between the presence and severity of MR and heart failure or death. Moderate or severe MR was associated with a large increase in the risk of heart failure (relative risk 3.44, 95% CI 1.74 to 6.82, P <0.001) and death (relative risk 1.55, 95% CI 1.08 to 2.22, P =0.019) among 30-day survivors independent of age, gender, EF, and Killip class. Conclusions— In the community, MR is frequent and often silent after MI. It carries information to predict heart failure or death among 30-day survivors independently of age, gender, EF, and Killip class. These findings, which are applicable to a large community-based MI cohort, suggest that the assessment of MR should be included in post-MI risk stratification.
Identification of Women's Coronary Heart Disease and Risk Factors Prior to First Myocardial Infarction
Yawn, Barbara P. , Wollan, Peter C. , Jacobsen, Steven J. , Fryer, George E., Roger, Véronique L.

Mayo Clinic

Journal of Women's Health | January 13, 2005 | Volume: 13 | Issue: 10 | Pages: 1087-1100

10.1089/jwh.2004.13.1087 | PMID 15650342 Get It

Alcoholism in a Coronary Care Unit Population
Juergens, Steven M., Hurt, R. Douglas , Offord, Kenneth P., Zarling, Kathleen K., Zemke, Kimberly, ANDERSON, LOIS L., Fredrickson, Paul, Miller, Fletcher A.

Mayo Clinic

Journal of Addictive Diseases | January 12, 2005 | Volume: 12 | Issue: 2 | Pages: 57-76

10.1300/j069v12n02_05 | PMID 8476943 Get It

α-Conotoxins ImI and ImII Target Distinct Regions of the Human α7 Nicotinic Acetylcholine Receptor and Distinguish Human Nicotinic Receptor Subtypes
Ellison, Michael J. , Gao, Fan , Sine, Steven M. , McIntosh, J. Michael , Wang, Hailong , Olivera, Baldomero M.

Mayo Clinic

Biochemistry | December 21, 2004 | Volume: 43 | Issue: 51 | Pages: 16019-16026

10.1021/bi048918g | PMID 15609996 Get It

Gemcitabine and ISIS-2503 for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma: A North Central Cancer Treatment Group Phase II Trial
Erlichman, Charles , Steen, Preston D. , Foster, Nathan R. , Moore, Dennis F., Rowland, Kendrith M. , Nair, Suresh , Tschetter, Loren K., Fitch, Tom R., Alberts, Steven R. , Schroeder, Mark A.

Mayo Clinic

Journal of Clinical Oncology | December 21, 2004 | Volume: 22 | Issue: 24 | Pages: 4944-4950

10.1200/jco.2004.05.034 | PMID 15611509 Get It

Purpose Gemcitabine remains the standard therapy for metastatic pancreatic adenocarcinoma (ACA), but has limited activity. ISIS-2503 is an antisense compound directed against H-ras with preclinical activity against pancreatic ACA in tumor models. The combination of ISIS-2503 and gemcitabine has been evaluated in a prior phase I study. Methods Patients with metastatic or locally advanced pancreatic ACA not amenable to surgery or local radiation received gemcitabine 1,000 mg/m2 intravenously over 30 minutes on days 1 and 8 and ISIS-2503 6 mg/kg/d as a continuous intravenous infusion over 14 days of an every-3-weeks cycle. Responses were monitored by radiologic imaging every 6 weeks. Results Forty-eight eligible patients were enrolled, 43 with metastatic disease. Median follow-up was 12.6 months (range, 2.2 to 16.8 months) for living patients. A median of four cycles of treatment was given (range, 1 to 18 cycles). All patients were assessable for response and toxicity. The 6-month survival percentage was 57.5% (95% CI, 44.9% to 73.5%) and the median survival was 6.6 months. The response rate was 10.4% (one complete response, four partial responses). Clinically significant toxicity was limited except for one fatal pulmonary embolism. Conclusion This study shows a promising response rate to the combination of gemcitabine and ISIS-2503 in patients with pancreatic ACA. The observed 6-month survival rate in these patients met our protocol-defined criteria for success. This regimen is tolerable, but is of unclear benefit. Additional studies evaluating the role of gemcitabine and ISIS-2503 in the treatment of pancreatic ACA should be considered.
Invariant Aspartic Acid in Muscle Nicotinic Receptor Contributes Selectively to the Kinetics of Agonist Binding
Lee, Won Yong , Sine, Steven M.

Mayo Clinic

The Journal of General Physiology | October 25, 2004 | Volume: 124 | Issue: 5 | Pages: 555-567

10.1085/jgp.200409077 | PMID 15504901 Get It

We examined functional contributions of interdomain contacts within the nicotinic receptor ligand binding site using single channel kinetic analyses, site-directed mutagenesis, and a homology model of the major extracellular region. At the principal face of the binding site, the invariant αD89 forms a highly conserved interdomain contact near αT148, αW149, and αT150. Patch-clamp recordings show that the mutation αD89N markedly slows acetylcholine (ACh) binding to receptors in the resting closed state, but does not affect rates of channel opening and closing. Neither αT148L, αT150A, nor mutations at both positions substantially affects the kinetics of receptor activation, showing that hydroxyl side chains at these positions are not hydrogen bond donors for the strong acceptor αD89. However substituting a negative charge at αT148, but not at αT150, counteracts the effect of αD89N, demonstrating that a negative charge in the region of interdomain contact confers rapid association of ACh. Interpreted within the structural framework of ACh binding protein and a homology model of the receptor ligand binding site, these results implicate main chain amide groups in the domain harboring αW149 as principal hydrogen bond donors for αD89. The specific effect of αD89N on ACh association suggests that interdomain hydrogen bonding positions αW149 for optimal interaction with ACh.
Focused Cervical Exploration for Primary Hyperparathyroidism without Intraoperative Parathyroid Hormone Monitoring or Use of the Gamma Probe
Jacobson, Steven R., Heerden, Jon A. van, Farley, David R. , Grant, Clive S., Thompson, Geoffrey B. , Mullan, Brian P., Curlee, Kathleen J.

Mayo Clinic

World Journal of Surgery | October 14, 2004 | Volume: 28 | Issue: 11 | Pages: 1127-1131

10.1007/s00268-004-7469-2 | PMID 15490069 Get It

AbstractSelected patients with primary hyperparathyroidism (pHPT) who have a positive preoperative sestamibi scan can be managed safely and successfully with a focused cervical exploration without either adjuvant intraoperative parathyroid hormone (PTH) monitoring or use of a gamma probe. This article reports a retrospective analysis of a consecutive series of patients surgically treated at a tertiary referral center. From August 1998 to August 2002, 100 patients (68 women, 32 men; mean age 63 years [range: 29–89 years]) underwent a focused cervical approach without intraoperative PTH monitoring or use of the gamma probe after perioperative sestamibi injection. The study group comprised 9% of all patients (n = 1063) undergoing cervical exploration for pHPT during the study period. Ninety patients underwent an initial exploration, and 10 others underwent repeat cervical exploration following prior parathyroid (n = 7) or thyroid (n = 3) operation. Sestamibi scanning correlated with one enlarged parathyroid gland in all patients. Other enlarged glands were, however, not demonstrated in three patients (true positive = 97%; false negative = 3%). The single enlarged glands excised in all patients had a mean weight of 795 mg (range: 90–3640) and were histologically compatible with an adenoma. Postoperatively, 97% of patients were eucalcemic. Three patients remained hypercalcemic (3%). Of the three patients with persistent hypercalcemia, one underwent successful re‐exploration with excision of a 500 mg second adenoma, whereas the other two patients (with confirmed familial HPT) remained hypercalcemic. Mean hospitalization was 0.5 days (range: 0–3 days). There was no operative mortality. No patients had permanent hypocalcemia. Postoperative morbidity occurred in three patients: two self‐limiting cervical hematomas and one permanent vocal cord paralysis. Selected patients with pHPT due to single‐gland disease and an unequivocally positive preoperative sestamibi scan can safely and successfully be managed with a focused unilateral cervical exploration without either intraoperative PTH monitoring or use of the gamma probe. Further experience with this surgical approach seems warranted to determine the overall cure rate, operative morbidity, and the sensitivity and specificity of preoperative localization studies.